1500; H-index: 22 (ISI Web of Science) Contact: Doctoral Program MolTag, Dept. of Pharmacology and Toxicology; http://moltag.univie.ac.at/, Office.moltag@univie.ac.at, phone: 01 4277 55320 " />1500; H-index: 22 (ISI Web of Science) Contact: Doctoral Program MolTag, Dept. of Pharmacology and Toxicology; http://moltag.univie.ac.at/, Office.moltag@univie.ac.at, phone: 01 4277 55320 " />

Donnerstag, 06. Dezember 2018, 17:15 - 18:00 iCal

MolTag Guest Lecture by Petrine WELLENDORPH, PhD

"Molecular Characterization of GABA Transporters and their Pharmacological Potential in Stroke"

UZA 2, Lecture Hall 5
Althanstraße 14, 1090 Vienna

Lecture


Doctoral Program ION CHANNELS AND TRANSPORTERS AS MOLECULAR DRUG TARGETS („MolTag“)

is pleased to invite you to the following lecture

"Molecular Characterization of GABA Transporters and their Pharmacological Potential in Stroke”

by Ass.Prof. Petrine WELLENDORPH, PhD

Dept. of Drug Design and Pharmacology, Univ. of Copenhagen

e-mail: pw@sund.ku.dk;

drug.ku.dk/employees/

on: Thursday, December 6th, 2018, 05:15 pm (17:15 Uhr)

at: UZA 2, Althanstr. 14, 1090 Vienna, Lecture Hall 5

 

ABSTRACT: Imbalances in GABA-mediated tonic inhibition are involved in several pathophysiological conditions. A classical way of controlling tonic inhibition is through pharmacological intervention with extrasynaptic GABAA receptors that sense ambient GABA and mediate a persistent GABAergic conductance. An increase in tonic inhibition may, however, also be obtained indirectly by inhibiting glial GABA transporters (GATs). These are sodium-coupled membrane transporter proteins that normally act to terminate GABA neurotransmitter action by taking up GABA into surrounding astrocytes. In my research group we are investigating the pharmacological potential of the GAT subtypes BGT1 and GAT3 in relation to ischemic stroke. The lecture will cover characterization of novel tool compounds including their binding sites, by molecular pharmacology methods, as well as in vivo pharmacology data from a mouse model of ischemic stroke, altogether underlining the potential of targeting GATs in stroke and related disorders.

 

RESEARCH PROFILE: My research is focused on basic molecular neuropharmacology related to the signalling molecules GABA and GHB in the mammalian brain. Techniques include molecular pharmacology (pharmacology assays, cell-culturing, characterization of ligands, expression studies, assay development) and in vivo/ex vivo pharmacology (autoradiography, primary cell culture, mouse models of ischemic stroke). The research is highly interdisciplinary and enjoys collaboration with both national and international groups in the fields of medicinal chemistry, in vitro and in vivo pharmacology, computational chemistry, proteomics and imaging.

 

SCIENTIFIC ACTIVITIES & LEADERSHIP: Head of Section (Jan-Jul 2018). Member of Research and Innovation Committee (2015-) and local board for Internal Affairs (2010-); Assistant Editor, Basic & Clinical Pharmacology & Toxicology (2017-). Research group leader 7-10 persons; Main supervisor for 8 postdocs (5 completed) and 10 PhD students (7 completed).

INNOVATION: Co-founder of Ceremedy Inc, Aug. 2018. Co-inventor on 1 patent.

SCIENTIFIC PRODUCTION & BIBLIOMETRICS: 62 peer-reviewed published papers incl. 1 patent and 4 book chapters; Sum of citations (without self-citations): >1500; H-index: 22 (ISI Web of Science)

 

Contact: Doctoral Program MolTag, Dept. of Pharmacology and Toxicology; moltag.univie.ac.at, Office.moltag@univie.ac.at, phone: 01 4277 55320

 

Zur Webseite der Veranstaltung


Veranstalter

MolTag Doctoral Program


Kontakt

Susanne Menschik-Zunzer
Department of Pharmacology and Toxicology, UZA 2
DK Molecular Drug Targets
01 4277 55320
susanne.menschik-zunzer@univie.ac.at, office.moltag@univie.ac.at